Gilead Sciences Inc. has divulged thienopyrrole compounds acting as Toll-like receptor 7 (TLR7) and/or TLR8 antagonists reported to be useful for the treatment of systemic lupus erythematosus (SLE), cutaneous lupus erythematosus, lupus nephritis and inflammatory disorders, among others.
Novadip Biosciences SA has raised an additional €40 million in a series B equity round and nondilutive funding to accelerate the clinical development of two of the company's investigational adipose stem cell (ASC)-derived tissue regeneration products.
Dystroglycanopathies are a subset of rare congenital muscular dystrophies (CMDs) caused by dysregulation in the assemblage of glycans on the α-dystroglycan (α-DG) transmembrane glycoprotein.
Based on an analysis of critical transcription factors, researchers have stratified rheumatoid arthritis (RA) into two subtypes where gene expression was driven by RAR-α or TGF-β, respectively. The findings, published in Nature Communications on Oct. 20, 2022, by researchers from the University of California, San Diego, give new insights into factors that affect the treatment response in RA, and could point to novel treatment strategies.
Vicore Pharma AB has divulged new angiotensin AT2 receptor (AGTR2) agonists reported to be useful for the treatment of rheumatoid arthritis, diabetic nephropathy, pulmonary arterial hypertension, myocardial infarction, pneumonia viral, sarcoidosis, idiopathic pulmonary fibrosis and systemic scleroderma (systemic sclerosis), among other disorders.
Vicore Pharma AB has divulged new angiotensin AT2 receptor (AGTR2) agonists reported to be useful for the treatment of rheumatoid arthritis, diabetic nephropathy, pulmonary arterial hypertension, myocardial infarction, pneumonia viral, sarcoidosis, idiopathic pulmonary fibrosis and systemic scleroderma (systemic sclerosis), among other disorders.
Ascidian Therapeutics Inc. secured $50 million in series A funding from its founder Apple Tree Partners to take a therapy based on its RNA exon editing technology into a first-in-human trial in ABCA4 retinopathy and to advance additional programs in neuromuscular, neurological, and rare disease indications.
Cabaletta Bio Inc. has announced CABA-201, a newly designed, fully human CD19 chimeric antigen receptor (CAR) containing a 4-1BB co-stimulatory domain.
Endpoint Health Inc. has announced a new precision immunology program targeting inflammation mediated by tissue factor (TF)-dependent intracellular signaling.
RSS
